http://www.isg.rhul.ac.uk/akay/teaching/... http://www.isg.rhul.ac.uk/akay/teaching/...
  • pharmacie en ligne paris http://gev.industrie.gouv.fr/CACHE/well/...
  • generique levitra mg viagra generique viagra quebec
    medicament cialis 5mg viagra express france levitra medicinale acheter clomifene viagra 100 mg baclofen generika viagra india achat rapide viagra
    http://www.periodiques-caraibeamazonie.f... generique viagra suisse viagra pas cher veille pharmaceutique
  • cialis y viagra pack acheter cialis viagra acquista cialis generico
  • Tag Archive | "cetuximab"

    AACR says that new drug may assist therapy for Head and Neck Cancer

    Monday, September 22, 2014

    0 Comments

    Source: hcplive.com Author:    THURSDAY, Sept. 18, 2014 (HealthDay News) — The investigational drug alpelisib (previously known as BYL719) appears to inhibit activation of the pathway that leads to resistance to cetuximab, an anti-epidermal growth factor receptor agent used in the treatment of head and neck cancer. These findings were presented at the American Association […]

    Continue reading...

    Targeted radiation, drug therapy combo less toxic for recurrent head, neck cancers

    Wednesday, September 17, 2014

    0 Comments

    Source: medicalxpress.com Author: University of Pittsburgh Schools of the Health Sciences Patients with a recurrence of head and neck cancer who have previously received radiation treatment can be treated more quickly, safely and with fewer side effects with high doses of targeted radiation known as Stereotactic Body Radiation Therapy (SBRT) in combination with a drug […]

    Continue reading...

    Docetaxel regimen tops cisplatin in head and neck cancer

    Saturday, July 19, 2014

    0 Comments

    Source: www.cancernetwork.com Author: Anna Azvolinsky, PhD A phase II study has demonstrated that combining docetaxel-based chemoradiotherapy and the antibody cetuximab postoperatively in patients with high-risk squamous cell carcinoma of the head and neck led to improved disease-free and overall survival, with no unexpected toxicities. The results of the study were published in the Journal of […]

    Continue reading...

    An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents

    Saturday, July 12, 2014

    0 Comments

    Source: 7thspace.com Author: staff The combination platinum, 5-fluorouracil (5-FU) and cetuximab is the standard first-line regimen of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). Due to the toxicity of this treatment, alternative therapies are often offered to patients. The aim of this study was to evaluate the overall survival obtained with a […]

    Continue reading...

    Lower radiation dose may be given to HPV-positive head and neck cancer patients

    Friday, June 20, 2014

    0 Comments

    Source: Vanderbilt University Published: June 19, 2014 By: Dagny Stuart   A new study suggests that lowering the dose of radiation therapy for some head and neck cancer patients may improve outcomes and cause fewer long-term side effects. The research was presented by lead author Anthony Cmelak, M.D., professor of Radiation Oncology at Vanderbilt-Ingram Cancer […]

    Continue reading...

    Low-dose IMRT may be safe for patients with HPV-positive head and neck cancer

    Tuesday, June 3, 2014

    0 Comments

    Source: www.oncologypractice.com Author: Laura Nikolaides Lower-dose radiation therapy may be safe for some patients with human papillomavirus (HPV)-positive oropharyngeal cancer, decreasing the risk of often long-term side effects, such as trouble swallowing, dry mouth, loss of taste, neck stiffness, and thyroid problems, investigators reported at the annual meeting of the American Society of Clinical Oncology. […]

    Continue reading...

    Experimental EGFR inhibitor added nothing but rash

    Wednesday, March 19, 2014

    0 Comments

    Source: www.oncologypractice.com Author: Neil Osterweil, Oncology Report Digital Network The addition of the experimental targeted agent zalutumumab to primary curative chemoradiation for head and neck cancers did not improve locoregional control, disease-specific survival, or overall survival at 3 years of follow-up. The only thing that zalutumumab added to therapy was a skin rash in the […]

    Continue reading...

    PTEN loss, PIK3CA mutation predicted resistance to cetuximab in HNSCC

    Monday, June 3, 2013

    0 Comments

    June 2, 2013 Source: Helio.com   CHICAGO — PTEN loss or PIK3CA mutation predicted resistance to treatment with cisplatin plus cetuximab in a cohort of patients with head and neck squamous cell carcinoma, according to phase 3 study results presented at the ASCO Annual Meeting. “Cetuximab is the only targeted therapy in use in head […]

    Continue reading...

    Erbitux add-on falls short in esophageal cancer

    Monday, January 28, 2013

    0 Comments

    Source: www.medpagetoday.com Author: Charles Bankhead, Staff Writer, MedPage Today The addition of a targeted agent to definitive chemoradiation failed to improve survival in an unselected population with esophageal cancer, a randomized trial showed. In fact, patients who received cetuximab (Erbitux) with chemoradiation had significantly worse overall survival (OS) reflected in a 50% increase in the […]

    Continue reading...

    Scientists find new way to boost cancer drugs

    Monday, January 21, 2013

    0 Comments

    Source: www.drbicuspid.com Author: DrBicuspid Staff Shutting down a specific pathway in cancer cells appears to improve the ability of common drugs to wipe those cells out, according to new research from scientists at Fox Chase Cancer Center (Cancer Discovery, January 2013, Vol. 3:1, pp. 96-111). The new approach appears to enhance the tumor-killing ability of […]

    Continue reading...